Form 4: Protagonist CMO Sells Shares for Tax Obligations

Protagonist Therapeutics' Chief Medical Officer, Arturo Molina, sold 9,514 shares of common stock at $82.48 per share to cover tax withholding obligations.

Summary

• Arturo Molina, MD, Chief Medical Officer of Protagonist Therapeutics, Inc. (PTGX), reported a sale of common stock.
• The transaction occurred on January 20, 2026.
• Molina disposed of 9,514 shares of common stock at a price of $82.48 per share.
• The sale was executed to cover tax withholding obligations incurred upon the settlement of restricted stock units.
• Following this transaction, Molina beneficially owns 97,266 shares of common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations from RSU vesting, which is a neutral event. The 10b5-1 plan further reinforces its pre-planned nature, mitigating any negative sentiment typically associated with insider sales.

Positives

• The sale was explicitly for tax withholding obligations, indicating a non-discretionary transaction rather than a lack of confidence in the company.
• The transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not a reaction to recent events.

Negatives

• A significant number of shares (9,514) were sold, reducing the officer's direct beneficial ownership.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports an insider transaction.

Industry Context

This filing details a routine insider transaction, specifically a sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units. Such transactions are common across industries for executive compensation and tax management, and typically do not reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• The sale of shares to cover tax obligations upon RSU vesting is a standard and widely accepted practice for executives across various industries, aligning with typical compensation and tax planning strategies.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in the Chief Medical Officer's direct beneficial ownership, but the stated reason (tax withholding) suggests it is not indicative of a lack of confidence in the company's future prospects.

Key Dates

Recommendation

The reported insider sale by the Chief Medical Officer is a non-discretionary transaction to cover tax obligations from restricted stock unit vesting, executed under a Rule 10b5-1 plan. This is a routine event and does not signal a change in the company's fundamentals or management's confidence. Therefore, it provides no new information to warrant a change in investment thesis, suggesting a 'hold' recommendation based solely on this filing.

Keywords

Protagonist Therapeutics, PTGX, Insider Trading, Form 4, Stock Sale, Chief Medical Officer, Arturo Molina, Tax Withholding, Restricted Stock Units, 10b5-1 Plan